Neuren Pharmaceuticals Limited (ASX:NEU – Get Free Report) insider Joseph(Joe) Basile acquired 5,000 shares of the company’s stock in a transaction dated Wednesday, September 13th. The stock was acquired at an average cost of A$11.99 ($7.74) per share, with a total value of A$59,950.00 ($38,677.42).
Neuren Pharmaceuticals Price Performance
About Neuren Pharmaceuticals
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome.
Further Reading
- Five stocks we like better than Neuren Pharmaceuticals
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 2 Recession-Proof Intelligence Stocks to Defend Your Portfolio
- How to Invest in the Best Canadian Stocks
- 5 Reasons Mullen Automotive is About to Turn a Corner
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Qualcomm and Apple Forge Ahead with New Modem Partnership
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
